Search citation statements
Paper Sections
Citation Types
Year Published
Publication Types
Relationship
Authors
Journals
S Carboplatin/cisplatin Hyponatraemia due to SIADH: case reportA 68-year-old man with small-cell lung carcinoma developed hyponatraemia due to syndrome of inappropriate anti-diuretic hormone (SIADH) during treatment with cisplatin and then experienced a recurrence during treatment with carboplatin [dosages and routes of administration not stated].The man, who was a smoker, started receiving cisplatin with hydration; his sodium level was 138 mmol/L. On the evening of day 1, he was re-admitted with sudden-onset seizures and coma. He had a blood sodium level of 107 mmol/L, a plasma osmolality of 224 mOsm/kg water, a serum uric acid level of 212 µmol/L; his natriuresis was > 20 mmol/L.The man received treatment including demeclocycline and diuretics with rapid correction of his sodium level and his neurologically symptoms resolved. Cisplatin was replaced by carboplatin at a 75% dose for his second course of chemotherapy; his sodium level was 138 mmol/L. On day 2, he presented with severe hyponatraemia (115 mmol/L) and confusion. His condition resolved. Prior to his third course of chemotherapy, his sodium level was 138 mmol/L. He received carboplatin and developed hyponatraemia again (119 mmol/L) without neurological symptoms. His condition quickly resolved.Author comment: In our case, the patient presented with severe hyponatraemia after each course of chemotherapy. At the time of the first episode of hyponatraemia (day 1 of the first course), his blood sodium level was 107 mmol/L, his calculated plasma osmolality was 224 mOsm/kg of water, and his natriuresis was greater than 20 mmol/L. These results correspond with the criteria for SIADH.
S Carboplatin/cisplatin Hyponatraemia due to SIADH: case reportA 68-year-old man with small-cell lung carcinoma developed hyponatraemia due to syndrome of inappropriate anti-diuretic hormone (SIADH) during treatment with cisplatin and then experienced a recurrence during treatment with carboplatin [dosages and routes of administration not stated].The man, who was a smoker, started receiving cisplatin with hydration; his sodium level was 138 mmol/L. On the evening of day 1, he was re-admitted with sudden-onset seizures and coma. He had a blood sodium level of 107 mmol/L, a plasma osmolality of 224 mOsm/kg water, a serum uric acid level of 212 µmol/L; his natriuresis was > 20 mmol/L.The man received treatment including demeclocycline and diuretics with rapid correction of his sodium level and his neurologically symptoms resolved. Cisplatin was replaced by carboplatin at a 75% dose for his second course of chemotherapy; his sodium level was 138 mmol/L. On day 2, he presented with severe hyponatraemia (115 mmol/L) and confusion. His condition resolved. Prior to his third course of chemotherapy, his sodium level was 138 mmol/L. He received carboplatin and developed hyponatraemia again (119 mmol/L) without neurological symptoms. His condition quickly resolved.Author comment: In our case, the patient presented with severe hyponatraemia after each course of chemotherapy. At the time of the first episode of hyponatraemia (day 1 of the first course), his blood sodium level was 107 mmol/L, his calculated plasma osmolality was 224 mOsm/kg of water, and his natriuresis was greater than 20 mmol/L. These results correspond with the criteria for SIADH.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.